What We're Reading: Page 45
Industry reads hand-picked by our editors
Jul 31, 2024
Jul 30, 2024
-
CNN
Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
-
MIT Technology Review
Controversial CRISPR scientist promises “no more gene-edited babies” until society comes around
-
C&EN
The future of science publishing
-
NPR
Ozempic’s biggest side effect: Turning Denmark into a ‘pharmastate’?
Jul 29, 2024
Jul 26, 2024
Jul 25, 2024
Jul 24, 2024
-
The New York Times
A Disease That Makes Children Age Rapidly Gets Closer to a Cure
-
BioSpace
FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm
-
New England Journal of Medicine
The Real Purpose of PrEP — Effectiveness, Not Efficacy
Jul 23, 2024
-
Reuters
Drug giants eye China for deals despite growing Sino-US tensions
-
Financial Times
Novartis warns prostate cancer drug price will remain high
-
FirstWord Pharma
With IPO on ice, radiopharm developer Telix to raise nearly $400M in bond sale
-
KFF Health News
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Previous
